The U.S. Food and Drug Administration took action to help increase the supply of ventilators, ventilator tubing connectors, and ventilator accessories, as well as filtering facepiece respirators (FFRs) due to shortages during COVID-19, as part of our commitment to ease burdens on the health care system during this pandemic.
Cepheid today announced it has received Emergency Use Authorization (EUA) from the U.S. Food & Drug Administration (FDA) for Xpert® Xpress SARS-CoV-2, a rapid molecular diagnostic test for qualitative detection of SARS-CoV-2, the virus causing COVID-19. The test has been designed to operate on any of Cepheid's more than 23,000 automated GeneXpert® Systems worldwide, with a detection time of approximately 45 minutes.
L'azienda Cepheid ha annunciato di aver ricevuto l'autorizzazione all'uso di emergenza dalla Food & Drug Administration (Fda) statunitense per Xpert* Xpress SARS-CoV-2, un rapido test diagnostico molecolare per il rilevamento qualitativo di Sars-CoV-2, il virus che causa Covid-19.
Continua a leggere "Diagnosi Coronavirus, FDA: ok test in 45 minuti" »
EMA is aware of reports, especially on social media, which raise questions about whether non-steroidal anti-inflammatory medicines (NSAIDs) such as ibuprofen could worsen coronavirus disease (COVID-19).
The virus that causes coronavirus disease 2019 (COVID-19) is stable for several hours to days in aerosols and on surfaces, according to a new study from National Institutes of Health, CDC, UCLA and Princeton University scientists in The New England Journal of Medicine.
Continua a leggere "New coronavirus stable for hours on surfaces" »
La proteina spike (primo piano) consente al virus di entrare e infettare le cellule umane. Sul modello del virus, la superficie del virus (blu) è coperta da proteine a spillo (rosse) che consentono al virus di entrare e infettare le cellule umane.
Uno studio clinico di fase 1 che valuta un vaccino sperimentale progettato per proteggere contro la malattia da coronavirus 2019 (COVID-19) è iniziato al Kaiser Permanente Washington Health Research Institute (KPWHRI) di Seattle.
The spike protein (foreground) enables the virus to enter and infect human cells. On the virus model, the virus surface (blue) is covered with spike proteins (red) that enable the virus to enter and infect human cells.
A Phase 1 clinical trial evaluating an investigational vaccine designed to protect against coronavirus disease 2019 (COVID-19) has begun at Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle.
In late 2019, the first reports of an unknown respiratory infection—in some cases fatal—emerged from Wuhan, China. The source of that infection was quickly identified as a novel coronavirus, related to those that had caused outbreaks of Severe Acute Respiratory Syndrome (SARS) from 2002-2004 and Middle East Respiratory Syndrome (MERS) in 2012.
Continua a leggere "Novel coronavirus structure reveals targets for vaccines and treatments" »
Dr Hans Kluge, WHO Regional Director for Europe
Good morning. Thank you for inviting me to say a few words to you today.
Allow me to provide you with an update of the situation. As of today, we count over 80,000 cases of COVID-19 in 34 countries. Four new Member States – Afghanistan, Bahrain, Iraq, and Oman – reported cases of COVID-19 in the past 24 hours. 97% cases are reported from China and our thoughts are with all those families and communities affected by the disease and the health workers and authorities working tirelessly to treat and protect their populations.
Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients announced that it has released the first batch of mRNA-1273, the Company’s vaccine against the novel coronavirus, for human use.
